The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The esophageal cancer cohort of a phase 2 trial of E7389-LF (liposomal formulation of eribulin) + nivolumab.
 
Akira Ooki
Honoraria - Bristol Myers Squibb Foundation; Daiichi Sankyo; Merck Serono; Ono Pharmaceutical
 
Sachiko Yamamoto
No Relationships to Disclose
 
Hisato Kawakami
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo; Lilly Japan; Merck Serono; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo Co. Ltd.,; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kobayashi Pharmaceutical (Inst)
 
Tomoki Makino
No Relationships to Disclose
 
Akihito Kawazoe
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - MSD
Speakers' Bureau - Bristol-Myers Squibb; Daiichi Sankyo; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Sumitomo Dainippon Pharma (Inst); Taiho Pharmaceutical (Inst)
 
Toshiki Masuishi
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Amgen (Inst); Boehringer Ingelheim (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Syneos Health (Inst)
 
Takahiro Tsushima
Honoraria - Lilly Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Motohiro Hirao
No Relationships to Disclose
 
Naoki Takegawa
No Relationships to Disclose
 
Kaori Hino
No Relationships to Disclose
 
Satoru Iwasa
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Zymeworks (Inst)
 
Hiroki Hara
Honoraria - Asahi Kasei; Asahi Kasei; Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; Merck Serono; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb Japan; Daiichi Sankyo/UCB Japan; dainippon sumitomo; MSD; Ono Pharmaceutical
Research Funding - ALX Oncology (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Janssen Oncology (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Naoki Sumiyoshi
Employment - Ono Pharmaceutical
 
Daiko Matsuoka
Employment - Eisai
 
Yohei Otake
Employment - Eisai
 
Keisuke Yasuda
Employment - Eisai
 
Takao Takase
Employment - Eisai
 
Shuya Takashima
Employment - Eisai
 
Taro Semba
Employment - Eisai
Patents, Royalties, Other Intellectual Property - Eisai
 
Takashi Oshima
No Relationships to Disclose